EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data

Shouying Li, Jiaxin Feng, Shilin Zhang

Journal of Affective Disorders · 2026-06 · 402 · 121336

DOI: 10.1016/j.jad.2026.121336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-06. Verfasst von Shouying Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan 528000, China; Department of Urology, …. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Adverse Drug Reaction Reporting Systems, Pharmacovigilance, Sexual Dysfunction, Physiological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To describe and compare the reporting patterns and signal strengths of male sexual dysfunction associated with six commonly prescribed SSRIs in the FDA Adverse Event Reporting System. Adverse event data for six representative SSRIs, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, and escitalopram, were retrieved from the FAERS database, spanning from the first quarter of 2004 to the first quarter of 2025. Disproportionality analysis was conducted using both the reporting odds ratio (ROR) and proportional reporting ratio (PRR) to identify potential signals of adverse drug events associated with these medications. We analyzed 6,631,746 adverse drug event reports associated with SSRIs and detected significant disproportionality signals indicative of male sexual dysfunction in patients with depression. Across all SSRIs, erectile dysfunction was the most commonly reported adverse event [fluoxetine (ROR: 4.97, 95%CI: 4.25–5.82), paroxetine (ROR: 3.99, 95%CI: 3.53–4.5), sertraline (ROR: 6.11, 95%CI: 5.53–6.75), fluvoxamine (ROR: 1.08, 95%CI: 0.35–3.36), citalopram (ROR: 7.7, 95%CI: 6.81–8.69), and escitalopram (ROR: 7.93, 95%CI: 6.99–8.99)], followed by sexual dysfunction [fluoxetine (ROR: 11.94, 95%CI: 10.01–14.23), paroxetine (ROR: 11.39, 95%CI: 10.05–12.91), sertraline (ROR: 13.34, 95%CI: 11.86–15.01), fluvoxamine (ROR: 9.64, 95%CI: 5.01–18.56), citalopram (ROR: 15.09, 95%CI: 12.98–17.54), and escitalopram (ROR: 16.42, 95%CI: 14.11–19.12)]. This FAERS analysis detected significant disproportionality signals for male sexual dysfunction across SSRIs. Signal variation reflects reporting differences, not comparative risk, due to database limitations. These findings highlight the need for clinical vigilance and further investigation. • Leveraging the extensive US FDA FAERS database, this study provides a large-scale pharmacovigilance analysis of six common SSRIs and male sexual dysfunction. • Significant disproportionality signals for male sexual dysfunction, particularly erectile dysfunction and general sexual dysfunction, were identified for all SSRIs • The findings underscore the need for clinicians to consider specific, tailored management strategies for SSRI-associated sexual adverse effects in men.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsAdverse Drug Reaction Reporting SystemsPharmacovigilanceSexual Dysfunction, PhysiologicalErectile DysfunctionHumansMaleUnited StatesParoxetineSertralineFluvoxamineCitalopramFluoxetineAdultEscitalopramMiddle Aged

Stichwörter der Autor:innen

Adverse eventFAERSSSRISexual dysfunction

Substanzen

Selective Serotonin Reuptake InhibitorsParoxetineSertralineFluvoxamineCitalopramFluoxetineEscitalopram

Autor:innen und Institutionen

  • Department of Urology, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan 528000, China; Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzho…
  • Department of Urology, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan 528000, China.
  • Department of Urology, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan 528000, China. Electronic address: zhang_40_1@163.com.

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Li, S., Feng, J., & Zhang, S. (2026). Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. Journal of Affective Disorders, 402, 121336. https://doi.org/10.1016/j.jad.2026.121336

Vancouver

Li S, Feng J, Zhang S. Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. Journal of Affective Disorders. 2026;402:121336. doi:10.1016/j.jad.2026.121336

BibTeX
@article{Li2026,
  author = {Li, Shouying and Feng, Jiaxin and Zhang, Shilin},
  title = {Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {402},
  pages = {121336},
  doi = {10.1016/j.jad.2026.121336}
}
Kostenlos starten →